OKYO announces the appointment of Dr Rajkumar Patil as Chief Scientific Officer
OKYO Pharma Limited (OKYO.L) Appointment of Chief Scientific Officer
Omega Diagnostics Gp (ODX.L) CE-Mark: Mologic COVID19 lateral flow antigen test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it has CE-Marked Mologic Ltd’s (‘Mologic’) lateral flow antigen test for COVID-19, to
Omega Diagnostics Gp (ODX.L) UK Public Sector Contract disclosure
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that a UK Public Sector contract disclosure has been published yesterday in relation to
Omega Diagnostics Gp (ODX.L) Contract with Screen4
Contract with Screen4 for COVID-19 antibody laboratory-based testing service
Omega Diagnostics Gp (ODX.L) UK-RTC statement on AbC-19TM rapid antibody test
Lateral flow test data shows potential for companion diagnostic to the Pfizer-BioNTech COVID-19 vaccine
OKYO Pharma Limited (OKYO.L) Patent for treating Ocular Pain and Inflammation
OKYO Pharma has U.S. Patent Issued Covering its Lipid Conjugated Peptide Analogues for treating Ocular Pain and Inflammation
Omega Diagnostics Gp (ODX.L) AbC-19TM rapid antibody test performance data
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes
Omega Diagnostics Gp (ODX.L) Director/PDMR Shareholding
Director/PDMR Shareholding – Exercise of Options and Total Voting Rights
Omega Diagnostics Gp (ODX.L) UK Government contract and trading update
UK Government manufacturing contract Board appointment & trading update
Omega Diagnostics Gp (ODX.L) Update re AbC-19 Rapid Test & antibody test service launch
Update re AbC-19TM Rapid TestÂ
OKYO PHARMA LIMITED (OKYO.L) Filing patent application for the use of Chemerin
OKYO announces filing of a patent application covering the use of Chemerin and associated analogues to treat “cytokine storm” associated with COVID-19 and ARDS
